Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Soft tissue sarcomas: general review]

K Fizazi1, I Cojean, A Le Cesne

  • 1Service de médecine B, institut Gustave-Roussy, Villejuif, France.

Bulletin Du Cancer
|October 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A simple plan: chemotherapy-sparing approaches to early-stage and regional seminoma and nonseminoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Corrigendum to "Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)": [Ann Oncol 26 (2015) 2168-2173].

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Expression of antibody-drug conjugate targets in soft tissue sarcomas.

ESMO open·2025
Same author

Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysis.

ESMO open·2025

Soft tissue sarcomas are diverse cancers with unknown epidemiology. Key prognostic factors include grade, size, and location, with a 5-year survival around 50%.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Medical Oncology

Context:

  • Soft tissue sarcomas represent a heterogeneous group of neoplasms with incompletely understood epidemiology.
  • Recent advancements in genetic studies have improved understanding of these rare cancers.

Purpose:

  • To review current knowledge on soft tissue sarcoma prognosis, treatment modalities, and chemotherapy efficacy.
  • To highlight prognostic factors and compare different therapeutic approaches.

Summary:

  • Histologic grade, tumor size, and deep location are significant independent prognostic factors.
  • Conservative surgical treatment combined with radiotherapy is preferred over radical surgery, showing no survival difference.
  • While doxorubicin, ifosfamide, and DTIC are effective, polychemotherapy response rates remain below 50%; high-dose chemotherapy and newer agents like edatrexate and Taxotere show promise.

Related Experiment Videos

Impact:

  • Adjuvant chemotherapy offers a modest 5-year survival increase of 9%, while neoadjuvant chemotherapy facilitates conservative treatment.
  • Understanding these factors optimizes treatment strategies for soft tissue sarcoma patients.
  • Further research into novel chemotherapeutic agents and high-dose regimens is warranted.